Tetraphase Pharmaceuticals, Inc. (TTPH) Director L Patrick Gage Buys 3,880 Shares of Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Director L Patrick Gage acquired 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) opened at $6.00 on Tuesday. Tetraphase Pharmaceuticals, Inc. has a 1 year low of $3.57 and a 1 year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The business’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) earnings per share. equities research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post -2.88 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TTPH. JPMorgan Chase & Co. lifted its position in Tetraphase Pharmaceuticals by 88.2% during the first quarter. JPMorgan Chase & Co. now owns 23,115 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 10,834 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in Tetraphase Pharmaceuticals by 27.1% during the first quarter. TIAA CREF Investment Management LLC now owns 161,687 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 34,515 shares in the last quarter. Vanguard Group Inc. lifted its position in Tetraphase Pharmaceuticals by 16.4% during the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after buying an additional 230,420 shares in the last quarter. Geode Capital Management LLC lifted its position in Tetraphase Pharmaceuticals by 17.0% during the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock worth $2,880,000 after buying an additional 45,554 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Tetraphase Pharmaceuticals by 180.4% during the first quarter. Dimensional Fund Advisors LP now owns 634,300 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 408,078 shares in the last quarter. Institutional investors and hedge funds own 58.19% of the company’s stock.

Several analysts have commented on the company. ValuEngine lowered Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 30th. BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. HC Wainwright raised their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, November 6th. Finally, BMO Capital Markets raised their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $15.15.

TRADEMARK VIOLATION NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) Director L Patrick Gage Buys 3,880 Shares of Stock” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/tetraphase-pharmaceuticals-inc-ttph-director-l-patrick-gage-buys-3880-shares-of-stock.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

What are top analysts saying about Tetraphase Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetraphase Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit